HOOK News and Press, HOOKIPA Pharma Inc. From 11/14/22

HOOKIPA Pharma press release ( NASDAQ: HOOK ): Q3 GAAP EPS of -$0.25 beats by $0.02 . Revenue of $2.23M (-42.4% Y/Y) misses by $0.68M . For further details see: HOOKIPA Pharma GAAP EPS of -$0.25 beats by $0.02, revenue of $2.23M misses by $0.68M

Major oncology collaboration and license agreement secured with Roche to develop HB-700 for KRAS-mutated cancers and an additional undisclosed oncology candidate Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer a...

NEW YORK and VIENNA, Austria, Nov. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced it will release its third quarter 2022 financial res...

NEW YORK and VIENNA, Austria, Nov. 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in the Sidoti M...

3 Tips for Finding Popular Penny Stocks to Buy Investing in penny stocks can be a great way to make money, but it can also be very risky. There are a few things you need to know before you start investing in penny stocks . First, you need to understand exactly what is going on in th...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: arhendrix / Shutterstock Indonesia Energy (NYSEMKT: INDO ) stock is climbing higher on Thursday after the company announced the discovery of oil in one of its new wells . The big news here is the oil ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Hookipa (NASDAQ: HOOK ) stock is rocketing higher on Thursday after reaching a strategic collaboration and license agreement with Roche (OTCMKTS: RHHBF ). That agreement has the tw...

Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) signed a license agreement with  Hookipa Pharma ( NASDAQ: HOOK ) to develop immunotherapy HB-700 for KRAS-mutated cancers and a second undisclosed novel arenaviral immunotherapy. Under the agreement, Hookipa&#...

Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapy HOOKIPA to receive $25 million in upfront cash as well as potential future success-based milestone payments up to approximately $930 million for b...

The following slide deck was published by HOOKIPA Pharma Inc. in conjunction with this event. For further details see: HOOKIPA Pharma (HOOK) August-2022-Investor-Presentation